Express News | Arvinas Inc - Company's Obligations Under Original Agreement to Pay Yale Minimum Annual Royalties and Certain Other Annual Fees Have Been Eliminated
Express News | Arvinas Inc - Will Make Another $5.0 Mln Payment on First Anniversary of Signing
Express News | Arvinas Inc - in Connection With Signing of Amended License Agreement, Company Made a Payment of $14.95 Mln to Yale
Express News | Arvinas Inc - on June 14 Unit Entered Into an Amended and Restated License Agreement With Yale University
Express News | Arvinas Announces Promotions of Ian Taylor, Ph.d. to President of Research and Development and Angela Cacace, Ph.d. to Chief Scientific Officer
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announce
Arvinas (NASDAQ:ARVN Investor Three-year Losses Grow to 68% as the Stock Sheds US$99m This Past Week
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But the long term shareholders of Arvinas, Inc. (NASDAQ:ARVN) have had an unfortunat
Arvinas to Participate in Upcoming Investor Conferences
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today an
Express News | Arvinas- Due to Hsr Termination & Satisfaction of Closing Conditions of License Agreement, Asset Agreement, Novartis Pharma AG to Pay Co $150.0 Mln
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 c
Form 144 | Arvinas(ARVN.US) Insider Proposes to Sell 1.65 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 20, $Arvinas(ARVN.US)$ Insider Sean Cassidy intends to sell 50,000 shares of its common stock on May 20, with a total market value of approximately $1.65 million. Sean Ca
Buy Rating Affirmed for Arvinas Holding Company on Strong Clinical Trial Results and Competitive Market Positioning
Express News | HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price Target
Arvinas Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 170.86% HC Wainwright & Co. → $87 Reiterates Buy → Buy 05/09/2024 86.8% Wells Fargo $63 → $60 M
Buy Rating on Arvinas for Promising Breast Cancer Therapy and Market Potential
Express News | Arvinas Inc : Jefferies Cuts Target Price to $60 From $66
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Longeveron (LGVN) and EDAP TMS (EDAP)
Analysts Conflicted on These Healthcare Names: Zimmer Biomet Holdings (ZBH), Doximity (DOCS) and Arvinas Holding Company (ARVN)
Form 144 | Arvinas(ARVN.US) Insider Proposes to Sell 1.16 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 16, $Arvinas(ARVN.US)$ Insider Sean Cassidy intends to sell 35,000 shares of its common stock on May 16, with a total market value of approximately $1.16 million. Sean C
No Data